Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study. - Jackson TL; Boyer D; Brown DM; Chaudhry N; Elman M; Liang C; O'Shaughnessy D; Parsons EC; Patel S; Slakter JS; Rosenfeld PJ (JAMA ophthalmology, 2017)